Acute Lymphoblastic Leukemia Registry at Asan Medical Center

NCT ID: NCT01761682

Last Updated: 2018-07-20

Basic Information

• Recruitment Status: TERMINATED
• Total Enrollment: 200 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-01-31
• Study Completion Date: 2016-05-31

Brief Summary

The investigators would like to propose a prospective longitudinal observational cohort study for patients who will be diagnosed and/or treated for acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, to use the acquired data for fundamentals of other retrospective analysis.

Detailed Description

1. Acquisition of informed concent form

2. Data acquisition from medical record including

• demographic / disease-associated factors
• details of treatment, and its results
• complications during treatment
• genetic data
• survival outcome (upto 10 years)

3. Accumulation of data for 30 years

4. Use of data for other retrospective analysis (including Asan Medical center Cell Banking basic data)

Conditions

Leukemia, Acute Lymphoblastic; Precursor B-Cell Lymphoblastic Leukemia; Leukemia, Biphenotypic, Acute; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive; Lymphoblastic Lymphoma

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Ph-ALL

Diagnosed as ALL with Philadelphia-negative

Diagnosed as ALL

Intervention Type: OTHER

All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Ph+ALL

Diagnosed as ALL with Philadelphia-positive (including biphenotypic acute leukemia with Philadelphia-positive)

Diagnosed as ALL

Intervention Type: OTHER

All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Other ALL

Diagnosed as ALL of other type, including Burkitt leukemia

Diagnosed as ALL

Intervention Type: OTHER

All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Interventions

Diagnosed as ALL

All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047

Intervention Type: OTHER

Other Intervention Names

Diagnosed as acute lymphoblastic leukemia

Eligibility Criteria

Inclusion Criteria

• All patients who are diagnosed and/or treated as acute lymphoblastic leukemia at Asan Medical Center (including biphenotypic acute leukemia with Philadelphila-positive, Burkitt leukemia/lymphoma)
• 15 years of age and over
• All patients who give written consent according to guidelines at Asan Medical Center committee on human research

Exclusion Criteria

• Patients who refuse to give consent to registering

• Minimum Eligible Age: 15 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Asan Medical Center

OTHER

Sponsor Role: lead

Responsible Party

Dae-Young Kim

Assistant Professor

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Dae-Young Kim, MD, PhD

Role: PRINCIPAL_INVESTIGATOR

Associate Professor

Locations

Asan Medical Center

Seoul, , South Korea

Countries

South Korea

Other Identifiers

AMC-HEMREG-ALL

Identifier Type: -

Identifier Source: org_study_id